Worsening of psychosis or topiramate-induced adverse event?
Duggal
Harpreet S
HS
Singh
Ira
I
D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology*; D003511:Cyclohexanols / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D000078785:Mirtazapine; D011605:Psychoses, Substance-Induced / Q000150:complications*; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000008:administration & dosage; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D000077236:Topiramate; D000069470:Venlafaxine Hydrochloride
D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D003511:Cyclohexanols; D005632:Fructose; D008803:Mianserin; D000078785:Mirtazapine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors; D000077236:Topiramate; D000069470:Venlafaxine Hydrochloride